From START to finish: implications of the START study

Lancet Infect Dis. 2016 Jan;16(1):13-14. doi: 10.1016/S1473-3099(15)00477-6.

Authors

Kevin M De Cock¹, Wafaa M El-Sadr²

Affiliations

¹ Centers for Disease Control and Prevention, Village Market 00621, Nairobi, Kenya. Electronic address: [email protected].
² ICAP at Columbia University, Mailman School of Public Health, New York, NY, USA.

PMID: 26738819
DOI: 10.1016/S1473-3099(15)00477-6

No abstract available

MeSH terms

Anti-HIV Agents / administration & dosage
Anti-HIV Agents / therapeutic use*
Drug Administration Schedule
HIV Infections / drug therapy*
HIV Infections / prevention & control
HIV Infections / transmission
Humans
Patient Compliance
Pre-Exposure Prophylaxis
Randomized Controlled Trials as Topic

Substances

Anti-HIV Agents